NewsBenzingaFDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker Benzinga 2026.09.28 07:10 (GMT+0) Open on Benzinga Other news Signal restricts mobile screenshots as it confronts ‘existential threat’ of AI surveillance Why It’s Time to Buy the Pullback in Broadcom Stock A tale of two Nvidias These Are the Top 10 Largest IPOs Following Anthropic's Historic Market Debut Nvidia Has a New Problem, And It’s Not What You Think Tesla Begins FSD v15 Rollout to First-Wave Customers